The Daiichi Sankyo ? Ranbaxy deal may have set the tone for a large scale consolidation in the Indian pharmaceutical industry, but yet another crucial segment within life sciences is in for a shake-up, too. The Indian clinical research segment is all set to witness consolidation, with a few clinical research organisations (CROs) keen to sell out.
Sources say two CROs based in Mumbai and two in Hyderabad are on the block, and more are in the pipeline. Some bigger CROs are looking at merging with larger firms.